VOYAGER THERAPEUTICS INC (VYGR) Forecast, Price Target & Analyst Ratings
NASDAQ:VYGR • US92915B1061
4.45 USD
-0.42 (-8.62%)
At close: Mar 13, 2026
4.54 USD
+0.09 (+2.02%)
After Hours: 3/13/2026, 6:35:50 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VOYAGER THERAPEUTICS INC (VYGR).
Forecast Snapshot
Consensus Price Target
$15.30
+ 243.82% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.51
Revenue Estimate9.376M
ChartMill Buy Consensus
87.78%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.30
Upside
+ 243.82%
From current price of $4.45 to mean target of $15.30, Based on 18 analyst forecasts
Low
$8.08
Median
$12.24
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
18 Wall Street analysts provided a forecast for the next 12 months for VYGR. The average price target is 15.3 USD. This implies a price increase of 243.82% is expected in the next year compared to the current price of 4.45.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.78%
VYGR was analyzed by 18 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about VYGR.
In the previous month the buy percentage consensus was at a similar level.
VYGR was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-03-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-12-02 | Citigroup | Initiate | Buy |
| 2024-11-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-16 | Leerink Partners | Initiate | Outperform |
| 2024-08-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-07-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-14 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-03-26 | Guggenheim | Initiate | Buy |
| 2024-03-19 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.51
Revenue Estimate9.376M
Revenue Q2Q44.85%
EPS Q2Q4.69%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-0.03%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
VYGR is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.51 USD and the consensus revenue estimate is 9.38M USD.
The next earnings revenue estimate has been revised downward by 0.03% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 40.9M 9.36% | 250.008M 511.27% | 80.001M -68.00% | 36.243M -54.70% | 62.254M 71.77% | 74.839M 20.22% | 77.596M 3.68% | 59.874M -22.84% | 67.575M 12.86% | 225.73M 234.04% | 457.42M 102.64% | 650.89M 42.30% | |
| EBITDA YoY % growth | -44.61M 34.81% | 126.455M 383.47% | -75.756M -159.91% | -127.682M -68.54% | -117M 8.37% | -107.344M 8.25% | -123.981M -15.50% | -126.48M -2.02% | -136.017M -7.54% | 79.152M 158.19% | 535.81M 576.94% | 834.56M 55.76% | |
| EBIT YoY % growth | -50.8M 30.98% | 122.014M 340.19% | -80.487M -165.97% | -137.189M -70.45% | -90.71M 33.88% | -125.146M -37.96% | -138.404M -10.59% | -175.925M -27.11% | -192.077M -9.18% | -130.672M 31.97% | 16.559M 112.67% | 163.84M 889.43% | |
| Operating Margin | -124.21% | 48.80% | -100.61% | -378.52% | -145.71% | -167.22% | -178.36% | -293.83% | -284.24% | -57.89% | 3.62% | 25.17% | |
| EPS YoY % growth | -1.22 35.79% | 3.09 353.28% | -1.13 -136.57% | -2.13 -79.65% | -1.63 19.54% | -1.43 12.66% | -1.33 6.55% | -1.58 -18.20% | -1.67 -5.72% | 0.03 101.53% | 1.86 7,180.00% | 3.05 64.56% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.51 4.69% | -0.46 19.21% | -0.47 0.55% | -0.47 -1.30% | -0.43 15.19% | -0.46 0.33% | -0.49 -4.75% | -0.52 -11.63% |
| Revenue Q2Q % growth | 9.376M 44.85% | 11.018M 111.88% | 11.117M -16.82% | 8.622M -43.78% | 5.1M -45.61% | 5.1M -53.71% | 5.1M -54.12% | 5.1M -40.85% |
| EBITDA Q2Q % growth | -32.745M 2.77% | -32.033M 7.28% | -32.635M -18.32% | -33.966M -26.23% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -35.226M -1.54% | -33.021M 9.84% | -32.964M -7.75% | -34.848M -4.41% | -44.316M -25.81% | -46.527M -40.90% | -48.844M -48.17% | -51.27M -47.13% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
10.34%
EPS Next 5 Year
3.35%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
28.89%
Revenue Next 5 Year
13.27%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-14.55%
EBIT Next 5 Year
-12.11%
VOYAGER THERAPEUTICS INC / VYGR Forecast FAQ
What is the price target for VYGR stock?
18 analysts have analysed VYGR and the average price target is 15.3 USD. This implies a price increase of 243.82% is expected in the next year compared to the current price of 4.45.
When does VOYAGER THERAPEUTICS INC (VYGR) report earnings?
VOYAGER THERAPEUTICS INC (VYGR) will report earnings on 2026-05-04.
What are the consensus estimates for VYGR stock next earnings?
The consensus EPS estimate for the next earnings of VOYAGER THERAPEUTICS INC (VYGR) is -0.51 USD and the consensus revenue estimate is 9.38M USD.
What is the consensus rating for VYGR stock?
The consensus rating for VOYAGER THERAPEUTICS INC (VYGR) is 87.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.